NGM to Host Virtual R&D Day on December 9, 2020
November 16 2020 - 12:05PM
NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a
biotechnology company focused on discovering and developing
transformative therapeutics for patients, today announced it will
host a virtual R&D Day on December 9, 2020 at 12:00 pm ET.
The R&D Day will highlight NGM’s productive, 100+
researcher-led discovery engine and feature NGM’s pipeline of drug
candidates in liver and metabolic diseases (aldafermin and
MK-3655), retinal disease (NGM621) and cancer (NGM120 and NGM707).
NGM also plans to unveil an additional oncology candidate at the
event.
Members of NGM’s management and senior NGM scientists will
present the company’s pipeline of programs and the unmet patient
needs each aims to address. Guest speakers will include:
- Daniel Von Hoff,
M.D.,
F.A.C.P., Distinguished Professor, The Translational
Genomics Research Institute
- Arun Sanyal,
M.D.,
Professor, Internal Medicine, Virginia Commonwealth University
- Robert
Schreiber,
Ph.D.,
Distinguished Professor, Pathology & Immunology, Washington
University School of Medicine
- Charles Wykoff,
M.D.,
Ph.D.,
Director of Research at Retina Consultants Houston
As part of the event, NGM will host a fireside chat with
Roger M. Perlmutter,
M.D., Ph.D., President,
Merck Research Laboratories, and Dean Y.
Li, M.D.,
Ph.D., Senior Vice President of Discovery Sciences
and Translational Medicine, Merck Research Laboratories, to discuss
the collaboration between NGM and Merck. The two companies have an
ongoing broad, multi-year strategic collaboration to discover,
develop and commercialize novel therapies across a wide range of
therapeutic areas.
A live webcast of the event will be available at ir.ngmbio.com
under ‘Events & Presentations’. A replay of the webcast will be
archived on the NGM website for one year following the
presentation.
To register for the NGM R&D Day, please sign up here.
About NGM Biopharmaceuticals, Inc.
NGM is a biopharmaceutical company focused on discovering and
developing novel therapeutics based on scientific understanding of
key biological pathways underlying liver and metabolic diseases,
retinal diseases and cancer. We leverage our biology-centric drug
discovery approach to uncover novel mechanisms of action and
generate proprietary insights that enable us to move rapidly into
proof-of-concept studies and deliver potential first-in-class
medicines to patients. At NGM, we aspire to operate one of the most
productive research and development engines in the
biopharmaceutical industry, with multiple programs in clinical
development. Visit us at www.ngmbio.com for more information.
Investor
Contact:Alex Schwartzir@ngmbio.com |
Media
Contact:Liz Melonemedia@ngmbio.com |
NGM Biopharmaceuticals (NASDAQ:NGM)
Historical Stock Chart
From Mar 2024 to Apr 2024
NGM Biopharmaceuticals (NASDAQ:NGM)
Historical Stock Chart
From Apr 2023 to Apr 2024